Deudextromethorphan
Trials 9 · a red edge is where a trial was stopped
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Deudextromethorphan | “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide...” NCT04408755 ↗5“A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide...” NCT03896945 ↗ “AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type” NCT03393520 ↗ “AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Intermittent Explosive Disorder (IED)” NCT03420222 ↗ “18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)” NCT02442778 ↗ “AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q])” NCT04464564 ↗ |
| Known as | d6-dextromethorphan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02153502 ↗ |
| Known as | d6-DM | “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide...” NCT04408755 ↗7“A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide...” NCT03896945 ↗ “A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the...” NCT02446132 ↗ “AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type” NCT03393520 ↗ “AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Intermittent Explosive Disorder (IED)” NCT03420222 ↗ “18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)” NCT02442778 ↗ “Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]” NCT02442765 ↗ “AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q])” NCT04464564 ↗ |
| Known as | Deudextromethorphan Hydrobromide | “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide...” NCT04408755 ↗5“A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide...” NCT03896945 ↗ “AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type” NCT03393520 ↗ “AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Intermittent Explosive Disorder (IED)” NCT03420222 ↗ “18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)” NCT02442778 ↗ “AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q])” NCT04464564 ↗ |
| Known as | Deuterated [d6]-Dextromethorphan Hydrobromide | “A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the...” NCT02446132 ↗1“Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]” NCT02442765 ↗ |
| Route | Oral | “Study medication will be administered orally twice a day (BID)” NCT02153502 ↗ |